<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03472846</url>
  </required_header>
  <id_info>
    <org_study_id>MIDETE</org_study_id>
    <nct_id>NCT03472846</nct_id>
  </id_info>
  <brief_title>MiDeTe - microRNA Levels Under Denosumab and Teriparatide Therapy in Postmenopausal Osteoporosis</brief_title>
  <official_title>MicroRNAs Levels in Women With Postmenopausal Osteoporosis Under Antiresorptive or Osteoanabolic Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>St. Vincent Hospital, Vienna</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is the quantitative determination of bone-specific microRNAs in the
      serum of postmenopausal women with osteoporosis during antiresorptive or osteoanabolic
      therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primarily the influence of the therapeutic treatment on the microRNA concentration in the
      serum (treatment-response) and the relation between microRNA serum levels and changes of the
      bone mineral density will be investigated.

      These data will help to examine the use of microRNAs as novel diagnostic biomarkers for the
      diagnosis of osteoporosis and targeted therapeutic treatment of patients.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>detection of microRNA concentration in serum</measure>
    <time_frame>24 months</time_frame>
    <description>influence of antiresorptive or osteoanabolic Treatment on microRNA levels in postmenopausal women with osteoporosis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>microRNAs and changes in bone metabolism under treatment</measure>
    <time_frame>24 months</time_frame>
    <description>correlation of microRNA with bone turnover markers, fracture risk, BMD</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Postmenopausal Osteoporosis</condition>
  <condition>Diabetes Type 2</condition>
  <arm_group>
    <arm_group_label>Group 1 - DMAB</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>postmenopausal women without type 2 diabetes mellitus treated with denosumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 - TPTD</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>postmenopausal women with type 2 Diabetes mellitus treated with teriparatide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3 - DMAB</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>postmenopausal women with type 2 diabetes mellitus treated with denosumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4 - TPTD</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>postmenopausal women without type 2 diabetes mellitus treated with teriparatid</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prolia, 60 Mg/mL Subcutaneous Solution</intervention_name>
    <description>antiresorptive treatment with Prolia</description>
    <arm_group_label>Group 1 - DMAB</arm_group_label>
    <arm_group_label>Group 3 - DMAB</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Teriparatide</intervention_name>
    <description>osteoanabolic treatment with Forsteo</description>
    <arm_group_label>Group 2 - TPTD</arm_group_label>
    <arm_group_label>Group 4 - TPTD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Postmenopausal women

          -  Age 60-80 years

          -  T-score according to DXA: &lt;-2.5

          -  indication for osteoporosis therapy according to international guidelines

        Exclusion Criteria:

          -  Diabetes mellitus type 1

          -  renal insufficiency III-V Â°

          -  Cirrhosis hepatis (Child B or higher)

          -  Chronic alcohol abuse

          -  rheumatic disease (RA, SpA, SLE)

          -  Malignancies (&lt;5 years)

          -  Eating Disorder (anorexia nervosa, bulimia)

          -  bone-specific pretreatment (DMAB, TPTD, strontium ranelate, SERMs) Bisphosphonate
             treatment is allowed
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Roland Kocijan, M.D.</last_name>
    <phone>+431599886600</phone>
    <email>roland.kocijan@bhs.at</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Zora Messner, M.D.</last_name>
    <phone>+431599886145</phone>
    <email>zora.messner@bhs.at</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Medical University Vienna; St. Vincent Hospital</name>
      <address>
        <city>Vienna</city>
        <zip>1060</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Muschitz, M.D.</last_name>
      <phone>+43159988</phone>
      <phone_ext>2119</phone_ext>
      <email>christian.muschitz@bhs.at</email>
    </contact>
    <contact_backup>
      <last_name>Zora Messner, M.D.</last_name>
      <phone>+43159988</phone>
      <phone_ext>6145</phone_ext>
      <email>zora.messner@bhs.at</email>
    </contact_backup>
    <investigator>
      <last_name>Roland Kocijan, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Zora Messner, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christian Muschitz, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Heinrich Resch, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Judith Haschka, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 14, 2018</study_first_submitted>
  <study_first_submitted_qc>March 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 21, 2018</study_first_posted>
  <last_update_submitted>March 20, 2018</last_update_submitted>
  <last_update_submitted_qc>March 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Dr. Christian Muschitz</investigator_full_name>
    <investigator_title>OA Priv. Doz. Dr. Christian Muschitz</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Osteoporosis, Postmenopausal</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Denosumab</mesh_term>
    <mesh_term>Teriparatide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

